Aminoglutethimide is a clinically available drug that suppresses steroid biosynthesis by inhibiting enzymes such as cytochrome P450scc and aromatase. Because several members of neurosteroids regulate glutamate receptors, we investigated the effect of aminogluthetimide on cell death induced by over-activation of glutamate receptors in CNS neurons. prevented NMDA receptor-dependent ischemic neuronal injury in organotypic cerebrocortical slice cultures, which was associated with suppression of glutamate 2 release during the ischemic insult.
Introduction
The term 'excitotoxicity' corresponds to damage of cells induced by aberrant activation of receptors for glutamate, the major excitatory neurotransmitter in CNS.
Over-activation of glutamate receptors typically results from excessive release of glutamate from synaptic terminals and/or glial cells, as observed in seizure-induced neuronal damage and ischemic neuronal injury (Nishizawa, 2001; Holmes, 2002) .
Reduced capacity for glutamate uptake from the extracellular fluid represents another mechanism of glutamate receptor over-activation, as suggested in pathogenesis of amyotrophic lateral sclerosis (Maragakis & Rothstein, 2004) . In addition, neuronal damage by glutamate synergistically with other insults has been implicated in neurodegenerative disorders including Alzheimer's, Parkinson's and Huntington's disease (Meldrum & Garthwaite 1990; Mattson, 2003) . In these ways, excitotoxicity plays a fundamental role in various pathological conditions in the brain.
Both neurons and glia can synthesize steroidal compounds called neurosteroids (Zwain & Yen, 1999) , which exert various influences on brain function (Mellon & Griffin, 2002; Reddy, 2003) . Neurosteroids modulate activities of neurotransmitter receptors including ionotropic glutamate receptors (Wu et al., 1991; Irwin et al., 1994; Weaver et al., 2000) , and several members of neurosteroids are shown either to suppress or to exacerbate excitotoxic neuronal injury. For example, dehydroepiandrosterone and its sulfated derivative protect hippocampal neurons from excitotoxic insults by NMDA, AMPA or kainate (Kimonides et al., 1998; Kurata et al., 2004) . Pregnanolone sulfate, a metabolite of progesterone, inhibits NMDA-induced membrane current and 4 intracellular Ca 2+ increase, and is neuroprotective against NMDA cytotoxicity Weaver et al., 1997; Shirakawa et al., 2002) . Moreover, Veiga et al. (2003) have demonstrated that pregnenolone and dehydroepiandrosterone, through aromatase-mediated conversion to estradiol, protect hippocampal hilar neurons against kainic acid cytotoxicity. In contrast, pregnenolone sulfate positively modulates NMDA receptor channels and exacerbates NMDA-induced neuronal death (Weaver et al., 1998; Yaghoubi et al., 1998; Shirakawa et al., 2002) .
These observations underscore the importance of neurosteroids in regulation of excitotoxicity-mediated neuronal damage. However, the overall influence of biosynthesis of endogenous neurosteroids on excitotoxic injury remains unclear, because some neurosteroids are protective but others are deleterious to neuronal cells.
Accordingly, we set out to examine the effect of aminoglutethimide ( Figure 1a ) on excitotoxicity-related neuronal injury. Aminoglutethimide inhibits cytochrome P450scc with an apparent K i value of 14 μM (Foster et al., 1983) : cytochrome P450scc
is an enzyme that catalyzes the first step of neurosteroid synthesis, namely, production of pregnenolone from cholesterol (Salhanick, 1982) . Aminoglutethimide also inhibits aromatase, an enzyme involved in production of estrogens, with an apparent K i value of 0.6 μM (Salhanick, 1982; Foster et al., 1983) . On the basis of these actions, clinical use of aminoglutethimide is approved in the United States for the treatment of hormone-dependent malignant tumors (Miller et al., 1987; Alshowaier et al., 1999) .
Here we report unexpected findings that aminoglutethimide protects cortical neurons from excitotoxic and ischemic injuries, probably through the mechanisms unrelated to 5 steroid biosynthesis.
Methods

Drugs and chemicals
Unless otherwise indicated, drugs and chemicals were obtained from Nacalai Tesque (Kyoto, Japan Chemicals (Osaka, Japan).
Cortical slice cultures
All experimental procedures were approved by our institutional animal experimentation committee, and animals were treated in accordance with the guidelines of the U.S.
National Institutes of Health regarding the care and use of animals for experimental procedures. Organotypic slice cultures were prepared with the procedures described previously (Shirakawa et al., 2002 (Shirakawa et al., , 2005 . Briefly, we anesthetized postnatal day 2 or 3 Wistar rats (from thirty-five mother rats in total) by chilling them in ice for 2-3 min, decapitated them, and removed the brain from the skull and cut it into two hemispheres.
Each hemisphere was cut into coronal slices of 300 μm thickness with a tissue chopper 6 (Narishige, Tokyo, Japan), and six cerebrocortical slices (seven slices in some cases) at the rostro-caudal level containing the caudate putamen were transferred onto a
Millicell-CM insert membrane (30 mm in diameter; Millipore, Bedford, MA, USA) in six-well plates. Culture medium, consisting of 50% minimal essential medium/HEPES (GIBCO, Invitrogen Japan, Tokyo, Japan), 25% Hanks' balanced salt solution (GIBCO) and 25% heat-inactivated horse serum (GIBCO) supplemented with 6.5 mg ml −1 glucose and 2 mM glutamine, 100 U ml −1 penicillin G potassium and 100
μg ml −1 streptomycin sulfate (GIBCO), was supplied at 0.7 ml per well. Culture medium was replaced with fresh medium on the next day of culture preparation, and thereafter, every two days. Slices were cultured in a humidified atmosphere of 5% CO 2 and 95% air at 34°C. From 10 days in vitro (DIV; 6 DIV in several experiments), cultures were maintained in serum-free medium consisting of 75% minimal essential medium/HEPES and 25% Hanks' balanced salt solution supplemented with 6.5 mg ml
glucose, 2 mM glutamine, 100 U ml −1 penicillin G potassium and 100 μg ml −1 streptomycin sulfate.
Cell death assay in slice cultures
Slice cultures were treated with excitotoxins, ionomycin and staurosporine for 24 h at 11 DIV with serum-free medium whose composition is described above. Chemical ischemia was applied to cultures at 11 DIV by transfer of culture inserts to the plates containing the conditioning solution. The conditioning solution was glucose-free
Ringer's buffer (124 mM NaCl, 4.9 mM KCl, 1.3 mM MgSO 4 , 2 mM CaCl 2 , 1.2 mM KH 2 PO 4 and 25.6 mM NaHCO 3 , pH 7.4) supplemented with 3 mM sodium azide and 10 mM 2-deoxyglucose were expressed as % of the standard injury. We occasionally encountered slices exhibiting deteriorated appearance or robust PI fluorescence before application of insults. These slices were excluded from cell death analysis.
LDH activity in culture medium was measured with Cytotoxicity Detection LDH kit (Kyokuto Pharmaceutical Industrial, Tokyo, Japan). Twenty-five μl of culture medium was mixed with 25 μl of LDH substrate mixture and 50 μl of 10 mM phosphate-buffered saline in a 96-well plate. After incubation for 1 h at room temperature, the reaction was stopped by addition of 100 μl of 1 M HCl and the absorbance was measured at 570 nm. Each value of absorbance was normalized with that in cultures receiving standard injury (200 μM NMDA for 24 h) as 100%.
Quantification of glutamate released from slice cultures
Amounts of glutamate released during chemical ischemia were measured with Amplex red glutamic acid/glutamate oxidase assay kit (Molecular Probes, Eugene, OR, USA) as described (Fujimoto et al., 2004) . After ischemic treatment, 50 μl of the ischemic conditioning solution in each well was collected and mixed with 50 μl of a reaction buffer containing Amplex red, glutamate oxidase, glutamate pyruvate transaminase, alanine and horseradish peroxidase. After incubation at 37°C, fluorescence of the reaction mixture emitted at 590 nm was measured with a fluorescence microplate reader (FlexStation; Molecular Devices, Sunnyvale, CA, USA) at an excitation wavelength of 555 nm.
Dissociated cortical culture and cell death assay
Primary cultures of dissociated cortical neurons were prepared from the cerebral cortex of fetal Wistar rats (17-19 days of gestation) derived from sixteen mother rats in total, as described previously (Shirakawa et al., 2002) . Single cells mechanically dissociated from the whole cerebral cortex were seeded onto 48-well plates coated with polyethylenimine (for cell death assay) or onto glass coverslips coated with polyethylenimine (for Ca 2+ measurement) at a density of 4.5 × 10 5 cells cml
. Cells were maintained at 37°C in a humidified 5% CO 2 atmosphere in Eagle's minimal essential medium (Nissui Pharmaceuticals, Tokyo, Japan) supplemented with glutamine (2 mM), glucose (11 mM in total), NaHCO 3 (24 mM), HEPES (10 mM), and 10%
heat-inactivated fetal bovine serum (1-7 DIV; JRH Biosciences, Lenexa, KS, USA) or 10% heat-inactivated horse serum (8-12 DIV; JRH Biosciences). Proliferation of non-neuronal cells was arrested by addition of 10 μM cytosine arabinoside at 6 DIV (Sigma-Aldrich Chemicals).
At 11 DIV, glutamate was added to the medium for 24 h at a final concentration of 300 μM, and cell death was evaluated by LDH release assay as mentioned above for slice culture experiments, except that 15 μl of culture medium was mixed with 30 μl of the LDH substrate mixture and 60 μl of 10 mM phosphate-buffered saline. Cultures treated with 10 mM glutamate for 24 h were used to determine the degree of the standard injury in each set of experiments. Absorbance values were normalized with the absorbance in cultures that received standard injury as 100%.
We also evaluated cell viability by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cultured cells were incubated in Eagle's medium containing 0.5 mg ml −1 MTT for 2 h and then solubilized with isopropanol, and the absorbance at 595 nm was measured. Viability was expressed as % of control, by setting the value of control cultures as 100% and the value of cultures receiving the standard injury (10 mM glutamate for 24 h) as 0%.
Measurement of intracellular Ca 2+ concentration
Glutamate-induced increases in intracellular Ca 2+ concentration ([Ca 2+ ] i ) were estimated with a Ca 2+ -sensitive fluorescent dye, fura-2 acetoxymethyl ester (Dojindo, Kumamoto, Japan), and a fluorescence imaging system (ARGUS-HiSCA, Hamamatsu Photonics, Shizuoka, Japan). Dissociated cortical neurons at 11-12 DIV cultured on a polyethylenimine-coated glass coverslip were incubated in Krebs-Ringer buffer (137 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1.5 mM CaCl 2 , 10 mM HEPES, 25 mM glucose, pH 7.4) containing 5 μM fura-2 acetoxymethyl ester and 0.01% cremophore EL (Sigma-Aldrich Chemicals) for 30 min at 37°C. After post-incubation in fura-2-free Krebs-Ringer buffer for at least 30 min, the coverslip was transferred to a recording chamber settled on the stage of an inverted fluorescence microscope. Fura-2 fluorescence obtained by excitation at wavelengths of 340 nm and 380 nm was recorded every 3 s at room temperature.
Data presentation and statistical analysis
Data are expressed as mean ± s.e.mean. 
Results
Aminoglutethimide protects cortical neurons in slice culture from excitotoxicity
Application of aminoglutethimide to cerebrocortical slice cultures from 1 DIV for 11 days, at concentrations up to 1000 μM, did not cause any changes in the number of Nissl-stained viable cortical neurons, indicating that the drug itself was devoid of Nissl staining (data not shown) and PI uptake (Figure 1e ). Neuroprotective effect of 1000 μM aminoglutethimide was also observed against cytotoxicity of 40 μM kainate, another non-NMDA receptor agonist (data not shown). On the other hand, neuronal injury induced by 24 h application of a Ca 2+ ionophore ionomycin (6 μM) was not affected by aminoglutethimide (Figure 1f ). Long-term treatment with aminoglutethimide was also without effect against cell death induced by 24 h application of 6 μM staurosporine (data not shown).
To verify whether or not a prolonged treatment was required for neuroprotection, we varied the periods of application of aminoglutethimide (Figure 2 ). Treatment with 1000 μM aminoglutethimide for 6 days from 6 DIV suppressed neuronal injury induced by treatment with 20 μM NMDA at 11 DIV. The degree of protection was comparable to that obtained by continuous treatment with 1000 μM aminoglutethimide from 1 DIV.
In contrast, treatment with aminoglutethimide during the first half of the cultivation period, i.e., from 1 to 6 DIV, did not provide a significant effect. Neither a shorter period of pretreatment from 10 DIV nor a simultaneous treatment at 11 DIV with aminoglutethimide suppressed NMDA cytotoxicity. The results were confirmed by counting of Nissl-stained surviving cells (Figure 2a ) and measurement of PI fluorescence ( Figure 2b ).
Neuroprotective effect of aminoglutethimide is unrelated to inhibition of steroid synthesis
To evaluate if the neuroprotective effect of aminoglutethimide is mediated by its effect on neurosteroid biosynthesis, we performed additional pharmacological examinations.
First, two drugs that inhibit steroidogenic pathways were tested for their potential neuroprotective effects. Trilostane competitively inhibits 3β-hydroxysteroid dehydrogenase, an enzyme involved in the conversion of pregnenolone, 17-hydroxypregnenolone and dehydroepiandrosterone into progesterone, 17-hydroxyprogesterone and Δ 4 -androsten-3,17-dione, respectively (Robel et al., 1995) .
14 The IC 50 value of trilostane on the enzyme activity has been reported to be 4.06 μM, when 1 μM pregnenolone is used as a substrate (Coirini et al., 2003) . Exemestane is a selective inhibitor of aromatase with a K i value of 4.3 nM (Di Salle et al., 1994; Miller et al., 2003) , therefore mimics part of the properties of aminoglutethimide as an enzyme inhibitor. Trilostane (3-30 μM) and exemestane (1-10 μM) were applied to cortical slice cultures continuously from 1 DIV, and NMDA cytotoxicity was examined at 11 DIV in the presence of these drugs. Neither of these drugs produced a significant effect on cell death induced by 20 μM NMDA, as assessed by Nissl staining (data not shown) and PI fluorescence (Figure 3a, b) . We could not test the effect of these drugs at higher concentrations because of their cytotoxicity.
Second, we examined whether the neuroprotective effect of aminoglutethimide against NMDA cytotoxicity could be reversed by application of neurosteroids.
Aminoglutethimide was applied to slice cultures from 6 DIV, simultaneously with 10 μM of pregnenolone, estrone, 17β-estradiol or estriol. To avoid any influences caused by steroidal compounds contained in serum, serum-free medium was used throughout the period of drug treatment. In these settings, aminoglutethimide again prevented neuronal death induced by 24 h application of 20 μM NMDA. However, neither of the steroids provided a significant influence on the neuroprotective effect of aminoglutethimide, as assessed by Nissl staining (Figure 3c ) and PI fluorescence (Figure 3d ). These results do not support the proposal that neuroprotection by aminoglutethimide is mediated by depletion of neurosteroids from the cortical tissue. Bastida et al. (2001) have reported that aminoglutethimide may act as an inhibitor of protein kinase A. Therefore, we examined the effect of KT5720, a selective protein kinase A inhibitor. However, long-term treatment with 0.1-1 μM KT5720 did not produce a significant effect on NMDA cytotoxicity (data not shown). ] i levels at 9 min after the onset of glutamate application (data not shown) did not significantly differ among different treatment groups. Therefore, inhibition of Ca 2+ influx is unlikely to mediate the neuroprotective effect of aminoglutethimide.
Effects of aminoglutethimide on glutamate cytotoxicity and glutamate-induced
Aminoglutethimide inhibits glutamate release and neuronal injury induced by ischemia in cortical slice culture
Finally, we examined effects of aminoglutethimide on ischemia-induced neuronal injury.
Simulated ischemia was achieved by incubation of cortical slice cultures with glucose-free Ringer's buffer containing sodium azide and 2-deoxyglucose . This treatment resulted in extracellular accumulation of glutamate during the treatment, and neuronal damage at 24 h after the treatment (Table 1) . Both consequences were increasingly apparent with longer periods of chemical ischemia. In the following experiments, 45 min was adopted as the period of ischemic treatment.
Application of 1 μM MK-801 during and after chemical ischemia almost completely protected cortical neurons (data not shown). Figure 5a shows that continuous treatment of cortical slice cultures with aminoglutethimide from 1 DIV suppressed ischemic neuronal injury. The protective effect of aminoglutethimide was in a concentration-dependent manner, which was significant at or over 30 μM and was almost complete at 1000 μM. Importantly, we found that prolonged treatment was not (Figure 5d ).
Discussion
The initial purpose of the present study was to verify potential roles of endogenous neurosteroids in regulation of excitotoxic neuronal injury in the cerebral cortex. We supposed that aminoglutethimide would be a useful pharmacological tool to address this issue, because the drug was expected to inhibit biosynthesis of neurosteroids by inhibiting cytochrome P450scc. We found that aminoglutethimide produced potent neuroprotective effects in two paradigms of neuronal injury. First, long-term treatment of cortical slice cultures with aminoglutethimide attenuated NMDA neurotoxicity. The unexpected finding was that supplementation of various steroids did not reverse the neuroprotective effect of aminoglutethimide. In particular, the ineffectiveness of pregnenolone, the immediate product of cytochrome P450scc, indicates that the observed effect of aminoglutethimide is not related to inhibition of neurosteroid biosynthesis. Second, aminoglutethimide prevented ischemic neuronal injury.
Although we did not examine the consequences of steroid supplementation in this paradigm, depletion of endogenous neurosteroids is unlikely to mediate neuroprotection by aminoglutethimide, because the drug effectively blocked ischemia-induced accumulation of extracellular glutamate and neuronal injury with only 1 h of pretreatment. Aminoglutethimide has been shown to attenuate excitotoxicity in the retina, but in this case, the effect is mediated by reduction of de novo biosynthesis of pregnenolone sulfate (Guarneri et al., 1998) . Steroidogenesis-independent neuroprotective actions of aminoglutethimide are unprecedented findings of the present study.
Several days of treatment were required for the protective actions of aminoglutethimide against NMDA neurotoxicity. In addition, long-term treatment with aminoglutethimide prevented neuronal death induced by excitotoxins including NMDA, AMPA and kainate, but had no effect against other cytotoxic agents such as ionomycin and staurosporine. Hence, a plausible mechanism of neuroprotection was that aminoglutethimide might decrease the number, or suppress the function, of ionotropic glutamate receptors, thereby attenuate excess Ca 2+ entry during excitotoxic insults. However, we did not observe a significant effect of aminoglutethimide on Our results in the present study do not necessarily exclude the roles of endogenous neurosteroids in regulation of neuronal injury. Substantial lines of evidence suggest that neurosteroids influence excitotoxic consequences in CNS neurons. For example, dehydroepiandrosterone and its sulfate protect hippocampal neurons from excitotoxic insults (Kimonides et al., 1998; Kurata et al., 2004) . Pregnenolone sulfate augments, whereas pregnanolone sulfate inhibits, NMDA receptor-mediated Ca 2+ influx and resultant cytotoxicity (Weaver et al., 1998; Shirakawa et al., 2002) . Because aminoglutethimide is likely to prevent excitotoxic injury through the mechanisms downstream of glutamate receptor activation, the effect of steroid depletion on neuronal death may well be occluded or masked by steroid-independent actions of aminoglutethimide. Alternative methods like specific knockdown of cytochrome P450scc expression may be required to evaluate the net effects of depletion of 20 endogenous neurosteroids.
In contrast to the effect on NMDA cytotoxicity, the neuroprotective effect of aminoglutethimide against ischemic neuronal injury was evident after a brief period of pretreatment. Because the degree of protection paralleled the decrease in the levels of glutamate accumulation during ischemic insult, we suggest that inhibition of aberrant release of glutamate is responsible for the effect of this drug against ischemic neuronal injury. Detailed mechanisms of inhibition of glutamate release by aminoglutethimide remain an open question. Various routes including exocytosis, reversed glutamate transport and efflux through volume-sensitive anion channels have been implicated in glutamate release from neurons and glia during ischemia (Nedergaard et al., 2002) . A nearly complete blockade of extracellular glutamate accumulation by 1000 μM aminoglutethimide, in spite of the presence of multiple routes of glutamate release, implies that the drug interferes with cellular events upstream of glutamate release, rather than individual release machineries.
In conclusion, we report here that aminoglutethimide exerted novel neuroprotective actions against excitotoxic and ischemic injuries. The mechanisms of actions do not involve any known pharmacological properties of this drug and should be addressed in further investigations. Aminoglutethimide has been used for therapies of hormone-dependent malignant tumors in the United States (Miller et al., 1987; Alshowaier et al., 1999) . Daily dose of aminoglutethimide is 250-1000 mg, and serum concentration of this drug in patients receiving 1000 mg dosing has been reported to be 9.0 μg ml -1 (38.7 μM; Miller et al., 1987) . In addition, Unger et al. (1986) (f) AGT was applied at indicated concentrations from 1 DIV, and ionomycin (6 μM) was applied for 24 h at 11 DIV in the presence of AGT. Cellular injury at 12 DIV was determined by PI fluorescence (n = 5-6 slices). In c-f, each value was normalized with that in slice cultures receiving the standard injury (200 μM NMDA for 24 h) as 100%.
Figure 2
Long-term pretreatment is required for aminoglutethimide (AGT) to protect neurons from NMDA cytotoxicity. AGT (1000 μM) was applied to cerebrocortical slice cultures for indicated periods (in DIV). NMDA (20 μM) was applied for 24 h at 11 DIV, and cellular injury at 12 DIV was determined by the number of Nissl-stained 28 surviving neurons (a, n = 5-6 slices) and intensity of PI fluorescence (b, n = 4-6 slices).
In b, each value was normalized with that in slice cultures receiving the standard injury (200 μM NMDA for 24 h) as 100%. *** P < 0.001 vs. NMDA alone. . n = 5-13 culture wells. * P < 0.05, ** P < 0.01, *** P < 0.001 vs.
chemical ischemia alone.
